Industry News
Pharmaceutical Industry News
With increased sales of its newer…
With increased sales of its newer drugs compensating for declining revenues from its multiple sclerosis portfolio, Biogen finally is positioned once again for a “growth story,” CEO Chris Viehbacher said Wednesday during the company’s second
As Teva proceeds down the more…
As Teva proceeds down the more muted growth path that it telegraphed early this year, the generics and innovative medicines hybrid isn’t letting a little sales slump affect its confidence in a budding portfolio of
A favorable regulatory resolution…
A favorable regulatory resolution with federal health authorities is clearing the way for Incyte’s Opzelura cream to reach blockbuster land ahead of schedule.
Hoffman wanted to be a part of the…
Hoffman wanted to be a part of the decision-making that "truly affects people" in healthcare, sparking a pivot from PR to pharma marketing, where she can use her natural creative and strategic lens to maximize
Manufacturers often focus on the…
Manufacturers often focus on the costs of hub transition. The bigger risk is inertia. Here's what staying fragmented is costing you.
The U.K. pharma marketing watchdog…
The U.K. pharma marketing watchdog has slammed AGB Pharma for misleadingly implying a lack of fertility considerations for its melatonin medicine, Adaflex.
Trump Will End Subsidies for Medicare Drug Premiums
Millions of older Americans could pay more for their prescription drug coverage next year.
What to Do if Your Estrogen Patch Is Out of Stock
Some hormone therapy patches are still in short supply. Here’s what experts recommend to avoid missing a dose.
The Considered+AI is an AI-native…
The Considered+AI is an AI-native agency that's been rooted in generative AI tools since its start in 2021.
Even though Hengrui Pharma has…
Even though Hengrui Pharma has resolved the manufacturing problems cited in a recent FDA complete response letter, a second citation stands in the way of the company and its partner Elevar Therapeutics’ fourth attempt at
Prediction Market Betting on Drug Trials and Approvals Sparks Concern About Undermining Research
Prediction markets on Kalshi and Polymarket now let people wager money on drug approvals. Kalshi also plans to allow bets on clinical trial results.
On the heels of favorable court…
On the heels of favorable court rulings, Johnson & Johnson has forged an agreement with law firms for plaintiffs that claim Johnson’s Baby Powder caused their ovarian cancer. J&J has proposed a $5.5 billion settlement
About half a year into his tenure…
About half a year into his tenure as GSK’s CEO, Luke Miels is launching a three-year restructuring designed to generate $2.5 billion in annual cost savings by 2029. The cost reductions will mainly be pulled
Baxter issued a voluntary recall…
Baxter issued a voluntary recall of one lot of cefazolin in dextrose injection after a report that cardboard was found in an IV infusion bag.
Havas Lynx has shaken up the…
Havas Lynx has shaken up the leadership of its New York team, expanding Claire Knapp’s role to cover the office and hiring Bruno Rebelo to head up its creative division.
Gilead’s “Up to Date” campaign…
Gilead's "Up to Date" campaign features comedians Nicole Byer and Devon Walker and looks to destigmatize HIV conversations in the Black community, which has historically been dispropriationally impacted by HIV.
Some five months after announcing…
Some five months after announcing the planned retirement of its longtime CEO Doug Ingram over what the helmsman dubbed an “ironic twist of fate” involving the health of his family members, Sarepta Therapeutics has found
Approval of the first-in-class…
Approval of the first-in-class norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) gives the Japanese drugmaker its “next major CNS launch” and positions the therapy to become a potential blockbuster in a large, under-penetrated market, Jefferies analysts
Roche’s cancer treatment Avastin…
Roche’s cancer treatment Avastin has long been employed as an off-label option for wet age-related macular degeneration patients. Now the FDA has endorsed a new formulation of the VEGF inhibitor for regulated use in the
Even as trial setbacks and…
Even as trial setbacks and pipeline adjustments rear their heads, AstraZeneca feels confident that its core business is on track to support the $80 billion revenue goal it’s set for 2030. And on the more